Hormel Foods (HRL) Q1 2026 earnings review
Stabilization Mode: Sales Grow, Turkey Business Goes
Hormel Foods delivered a 'solid start' to FY26, meeting preliminary expectations with $3.0 billion in sales and $0.34 Adjusted EPS. While earnings declined slightly YoY ($0.34 vs $0.35), the results mark a stabilization after the 'disappointing' shortfall of late FY25. The headline news is the definitive agreement to sell the whole-bird turkey business, a strategic move to excise the most volatile, commodity-exposed part of the portfolio. Management reaffirmed full-year guidance, signaling confidence that the worst of the inflationary shock is behind them.
🐂 Bull Case
The sale of the whole-bird turkey business to Life-Science Innovations is a major structural positive. This segment has been plagued by HPAI (bird flu) and commodity price swings, repeatedly causing earnings misses. Exiting it improves earnings quality and predictability.
Despite pricing and macro headwinds, Q1 26 marks the fifth consecutive quarter of organic net sales growth (+2%). The portfolio of branded proteins is showing resilience where peers are seeing volume degradation.
🐻 Bear Case
While sales are stable, profitability has not fully recovered. Adjusted EPS of $0.34 is down from $0.35 a year ago. The company is still working through the lag between high input costs (up 500bps in late FY25) and pricing realization.
The company is currently led by Interim CEO Jeff Ettinger. While experienced, the lack of a permanent CEO during a critical portfolio reshaping (Turkey sale) and restructuring period adds strategic uncertainty.
⚖️ Verdict: ⚪
Neutral. The divestiture of the turkey business is the right long-term move, and sales stability is encouraging. However, earnings growth remains elusive in the immediate term, and the company is in a transition period with interim leadership.
Key Themes
Portfolio Simplification: Turkey Divestiture
Hormel entered a definitive agreement to sell its whole-bird turkey business. This follows the FY25 divestiture of a sow farm operation. This is a critical step in de-risking the portfolio, moving away from commodity-heavy, biologically risky assets (bird flu) toward branded, value-added products. Management expects 'minimal impact' on FY26 guidance, suggesting the unit was contributing little to no profit.
Input Cost Hangover
The 'disappointing' FY25 results were driven by a 500 basis point surge in raw material costs (pork bellies +25%, trim +20%). Q1 26 results reflect the tail end of this shock. While pricing actions are in the market, the slight year-over-year dip in Adjusted EPS ($0.35 to $0.34) confirms that margins remain compressed relative to historical levels.
Transform and Modernize (T&M) Initiative
The company reaffirmed its commitment to the T&M cost-savings program. In FY25, this delivered significant savings (e.g., $100M-$150M projected). Continued execution here is vital to bridge the gap between high commodity costs and the delayed benefit of pricing actions.
Consumer Strains
Management noted a 'strained' and 'value-seeking' consumer environment. While organic sales grew 2%, this is a deceleration from the 6% growth seen in Q3 25, suggesting that price increases may be meeting resistance or that volume recovery is slowing.
Other KPIs
Stable. Reported sales were flat (~$2.99B in Q1 25 vs ~$3.0B in Q1 26), while organic sales grew 2%. This indicates that divestitures or FX are creating a ~2% drag on the top line.
Decelerating/Stabilizing. Down slightly from $0.35 in 25Q1, but consistent with the warning given in the Q4 25 call that Q1 earnings would decline YoY before accelerating later in the year.
Accelerating. Up from $0.31 in 25Q1 (GAAP). The gap between GAAP and Non-GAAP has narrowed compared to prior periods, indicating fewer one-time adjustment charges.
Guidance
Stable. Management reaffirmed this range. Given Q1 came in at 2%, the company is performing at the low end of the full-year target, implying a need for slight acceleration in Q2-Q4.
Accelerating vs FY25 ($1.37). The reaffirmation is key because Q1 ($0.34) annualizes to only $1.36. This implies management is confident in a significant earnings ramp in H2, driven by pricing realization and the Turkey divestiture.
Key Questions
Turkey Divestiture Proceeds
What are the financial terms of the whole-bird turkey sale? Will proceeds be used for debt paydown, buybacks, or reinvestment in the brand?
Margin Bridge for H2
With Q1 EPS annualizing below the FY26 guidance range, what specific drivers (commodity deflation vs. pricing) give confidence in the second-half ramp?
Volume vs Price Composition
In the reported 2% organic growth, what is the split between volume and price? Are volumes holding up as pricing actions from late FY25 hit the shelf?
CEO Search Update
What is the status of the permanent CEO search, and does the divestiture of the turkey business signal a shift in the profile of the candidate you are looking for?